---
figid: PMC11899595__cbm-22-177-g001
figtitle: Key molecular mechanisms/rationales for targeted agents in mantle cell lymphoma
  (MCL)
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11899595
filename: cbm-22-177-g001.jpg
figlink: /pmc/articles/PMC11899595/figure/F1/
number: F1
caption: Key molecular mechanisms/rationales for targeted agents in mantle cell lymphoma
  (MCL). In MCL, sustained activation of the B-cell receptor complex results in cellular
  growth and survival through multiple downstream signaling pathways. This figure
  shows the main signaling pathways and molecules involved in B cell receptor activation,
  such as Btk and NF-κB. Arrows point to downstream signaling molecules or their roles.
  White boxes indicate novel therapies that inhibit critical elements of this signaling
  pathway. Akt, protein kinase B; Bak, B-cell lymphoma-2 homologous antagonist killer;
  Bax, B-cell lymphoma-2–associated X protein; Bcl2, B-cell lymphoma protein-2; Btk,
  Bruton’s tyrosine kinase; CRBN, cereblon; DC, dendritic cell; IgH, immunoglobulin
  heavy chain; IL-2, interleukin-2; IKZF3, Aiolos; IZKF1, Ikaros; Lyn, Src-family
  kinase p53/56Lyn; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB;
  PI3K, phosphatidylinositol 3-kinase; PKCβ, protein kinase Cβ; PLCγ2, phospholipase
  Cγ2; Syk, spleen tyrosine kinase; Th, T-helper cell; Treg, T-regulatory cell
papertitle: Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission
  and overcomes high-risk factors in young patients with newly diagnosed mantle cell
  lymphoma
reftext: Yi Wang, et al. Cancer Biol Med. 2025 Feb 15;22(2).
year: '2025'
doi: 10.20892/j.issn.2095-3941.2024.0200
journal_title: Cancer Biology & Medicine
journal_nlm_ta: Cancer Biol Med
publisher_name: Chinese Anti-Cancer Association
keywords: Mantle cell lymphoma | immunochemotherapy | high-risk factors | minimal
  residual disease | adverse events
automl_pathway: 0.9525587
figid_alias: PMC11899595__F1
figtype: Figure
redirect_from: /figures/PMC11899595__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11899595__cbm-22-177-g001.html
  '@type': Dataset
  description: Key molecular mechanisms/rationales for targeted agents in mantle cell
    lymphoma (MCL). In MCL, sustained activation of the B-cell receptor complex results
    in cellular growth and survival through multiple downstream signaling pathways.
    This figure shows the main signaling pathways and molecules involved in B cell
    receptor activation, such as Btk and NF-κB. Arrows point to downstream signaling
    molecules or their roles. White boxes indicate novel therapies that inhibit critical
    elements of this signaling pathway. Akt, protein kinase B; Bak, B-cell lymphoma-2
    homologous antagonist killer; Bax, B-cell lymphoma-2–associated X protein; Bcl2,
    B-cell lymphoma protein-2; Btk, Bruton’s tyrosine kinase; CRBN, cereblon; DC,
    dendritic cell; IgH, immunoglobulin heavy chain; IL-2, interleukin-2; IKZF3, Aiolos;
    IZKF1, Ikaros; Lyn, Src-family kinase p53/56Lyn; mTOR, mammalian target of rapamycin;
    NF-κB, nuclear factor-κB; PI3K, phosphatidylinositol 3-kinase; PKCβ, protein kinase
    Cβ; PLCγ2, phospholipase Cγ2; Syk, spleen tyrosine kinase; Th, T-helper cell;
    Treg, T-regulatory cell
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MS4A1
  - KRT20
  - IL2
  - NELFCD
  - CRBN
  - CXCR4
  - CXCL12
  - PLCG1
  - PLCG2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - IKZF3
  - IKZF1
  - TP53
  - TP63
  - TP73
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - BAX
  - BAK1
  - BCL2
  - BTK
  - PRKCB
  - NFKB1
  - IGH
  - IGHV3OR16-7
  - IGHV3-69-1
  - CD79A
  - LYN
  - SYK
  - Lenalidomide
  - Everolimus
  - Bortezomib
  - Venetoclax
  - Ibrutinib
  - Nucleus
---
